Benefit-Risk Appraisal of Medicines: A systematic approach to decision-making

Benefit-Risk Appraisal of Medicines: A systematic approach to decision-making

Volumn , Issue , 2009, Pages 1-294

  Mussen, Filip ^a   Salek, Sam ^b   Walker, Stuart ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c CMR International Institute for Regulatory Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84948071507     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470748114     Document Type: Book

References (235)

1. Adis International (2009) Drug safety, http://pt.wkhealth.com/pt/re/drs/home.htm (accessed 4 February 2009).
2. Alexander, T. (2002). Risks should be balanced with benefits [rapid responses]. British Medical Journal, 324, eletters.
3. Andrews E. and Dombeck M. (2004) The role of scientific evidence of risks and benefits in determining risk management policies for medications. Pharmacoepidemiology and Drug Safety, 13, 599-608.
4. Anello, C. and O'Neill, R.T. (1996). Does research synthesis have a place in drug regulatory policy? Synopsis of issues: assessment of safety and post-marketing surveillance. Clinical Research & Regulatory Affairs, 13, 13-21.
5. Arlett, P. (2001) Risk benefit assessment. Pharmaceutical Physician, 12, 12-17.
6. Asscher, A.W. (1986) Strategy of risk-benefit analysis, in Iatrogenic Diseases, 3rd edn (eds P.F. D'Arcy and J.P. Green), Oxford University Press, New York.
7. Bass, R. (1987) Risk-benefit decisions in product license applications, in Medicines and Risk/ Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 127-34.
8. Beckmann, J. (1999) Basic aspects of risk-benefit analysis. Seminars in Thrombosis and Hemostasis, 25, 89-95.
9. Beermann, B. (2002) Communication of the benefit-risk assessment to patients: viewpoint of a health authority [presentation]. Drug Information AssociationAnnual Euromeeting 2002,March 6 2002, Basel, Switzerland. http://www.diahome.org/DIAHome/ (accessed 19 March 2009).
10. Belsey, J. (2001) Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. Journal of Clinical Research, 4,105-25.
11. Belton, V. and Stewart, T.J. (2002) Multiple Criteria Decision Analysis: an Integrated Approach, Kluwer Academic Publishers, Boston/Dordrecht/London.
12. Bjornson, D.C. (2004) Interpretation of drug risk and benefit: individual and population perspectives (2004). Annals of Pharmacotherapy, 38, 694-9.
13. Bjornsson, T.D. (1997) A matrix method for the evaluation of therapeutic agents: a framework based on disease process-oriented mechanisms of drug action and their effectiveness. Drug Information Journal, 31, 105-10.
14. Boada, J.N., Boada, C., Garcıa-Sáiz, M., et al. (2008) Net Efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance. PloS ONE, 3, e3580.
15. Bombardier, C., Laine, L., Reicin, A., et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343, 1520-8.
16. Bowen, A.J. (1993) Benefit/risk assessment: perspective of a patient advocate. Drug Information Journal, 27, 1031-5.
17. Briggs, A., Sculpher M. and Claxton, K. (2006) Decision Modeling for Health Economic Evaluation. Oxford University Press, New York.
18. Brimblecombe, R.W. (1987) Risk-benefit decisions in human administration, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 115-22.
19. Brown, J., Chapman, S. and Lupton, D. (1996) Infinitesimal risk as a public health crisis: news media coverage of a doctor-patient HIV contact tracing investigation. Social Science & Medicine, 43, 1685-95.
20. Brunet, P. (1999) Dictionary of the main reference terms: pharmaceutical law in the European Union; medicinal products for human use, Editions de Santé, Paris.
21. Burley, D.M. (1988) The rise and fall of thalidomide. Pharmaceutical Medicine, 3, 231-7.
22. Caldwell, D.M., Ades, A.E. and Higgins, J.P.T. (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal, 331, 897-900.
23. Califf, R.M. (2004) Benefit the patient, manage the risk: a system goal. Pharmacoepidemiology and Drug Safety, 13, 269-76.
24. Califf RM, for the CERTs Benefit Assessment Workshop Participants (2007) Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiology and Drug Safety, 16, 5-16.
25. Cheung, B.M.Y. and Kumana, C.R. (2001) Should decisions on treatment be based on absolute benefit rather than absolute risk? New Zealand Medical Journal, 114, 214-15.
26. Chuang-Stein, C. (1994) A new proposal for benefit-less-risk analysis in clinical trials. Controlled Clinical Trials, 15, 30-43.
27. Chuang-Stein, C. (1999) The role and analysis of benefit and risk in the development of new drugs, in The Benefit/Risk Ratio: a Handbook for the Rational use of Potentially Hazardous Drugs (eds H.C. Korting and M. Schafer-Korting M), CRC Press, Boca Raton FL, pp. 1-10.
28. Chuang-Stein, C., Entsuah, R. and Pritchett, Y. (2008) Measures for conducting comparative benefit:risk assessment. Drug Information Journal, 42, 223-33.
29. CIOMS Working Group III (1995) Guidelines for Preparing Core Clinical Safety Information on Drugs. CIOMS, Geneva.
30. CIOMS Working Group IV (1998) Benefit-risk Balance for Marketed Drugs: Evaluating Safety Signals. CIOMS, Geneva.
31. Clemen, R.T. (1996) Making Hard Decisions: an Introduction to Decision Analysis, 2nd edn, Duxbury Press, Pacific Grove.
32. Cocchetto, D.M. and Nardi, R.V. (1986) Benefit-risk assessment of investigational drugs: current methodology, limitations, and alternative approaches. Pharmacotherapy, 6, 286-303.
33. Cohen, J.T. and Neumann, P.J. (2007) What's more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits). Health Affairs, 26, 636-46.
34. Committee for Medicinal Products (1997a) Note for guidance on medicinal products in the treatment of Alzheimer's disease, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
35. Committee for Medicinal Products (1997b) Note for guidance on the investigation of drug interactions, European Medicines Evaluation Agency, London. Available from http://www.emea.europa.eu (accessed 7 April 2009).
36. Committee for Medicinal Products (1998) Points to consider on clinical investigation of medicinal products used in the treatment of osteoarthritis, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
37. Committee for Medicinal Products (1999) Note for guidance on clinical investigation of medicinal products in the treatment of cardiac failure, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
38. Committee for Medicinal Products (2003a) Note for guidance on evaluation of anticancer medicinal products in man, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
39. Committee for Medicinal Products (2003b) Points to consider on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
40. Committee for Medicinal Products (2003c) Note for guidance on clinical investigation of medicinal products in the treatment of lipid disorders. European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
41. Committee for Human Medicinal Products (2004) Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
42. Committee for Human Medicinal Products (2008) European Public Assessment Report for Avandia, European Medicines Evaluation Agency, London. http://www.emea.europa.eu (accessed 7 April 2009).
43. Conaway, M.R. and Petroni, G.R. (1996) Designs for phase II trials allowing for a trade-off between response and toxicity. Biometrics, 52,1375-86.
44. Costantino, J.P. (2001) Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. Annals of the New York Academy of Sciences, 949, 280-5.
45. Council for International Organizations of Medical Sciences IV Working Group (1998) Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals. World Health Organization, Geneva.
46. Council of the European Union (2003) Amended proposal for a Directive of the European Parliament and of the Council amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. DG C I; 2003 June 12. File no. 10450/03.
47. Cromie, B.W. (1987) Risk-benefit decisions in product license applications, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 135-6.
48. CropLife International (1997) Some aspects of benefit: risk evaluations in the registration of pesticides, 1 May 1997. Available from http://www.croplife.org (accessed 19 March 2009).
49. Cuervo, L.G. and Clarke, M. (2003) Balancing benefits and harms in health care: we need to get better evidence about harms. British Medical Journal, 327, 65-6.
50. Danjoh, K. (1999) Thinking globally: product development, registration, and marketing in the new millennium. Drug Information Journal, 33, 327-32.
51. Dawes, R., Faust, D. and Meehl, P.E. (1989) Clinical versus actuarial judgement. Science, 243, 1668-74.
52. Department of Transport, Local Government and the Regions (2000) Multi Criteria Analysis: a Manual. Office of the Deputy Prime Minister. Available from http://www.communities.gov.uk/publications/corporate/multicriteriaanalysismanual (accessed 19 March 2009).
53. Detsky, A.S., Naglie, G., Krahn, M.D., et al. (1997) Primer on medical decision analysis: part 1 -getting started. Medical Decision Making, 17, 123-5.
54. Dickinson, D. and Raynor, T.D.K. (2003) Ask the patients - they may want to know more than you think. British Medical Journal, 327, 861.
55. Djulbegovic, B., Hozo, I., Fields, K.K. and Sullivan, D. (1998) High-dose chemotherapy in the adjuvant treatment of breast cancer: benefit/risk analysis. Cancer Control, 5, 394-405.
56. Dowie, J. (1996a) 'Evidence-based', 'cost-effective' and 'preference-driven' medicine: decision analysis based medical decision making is the pre-requisite. Journal of Health Services Research and Policy, 1, 104-13.
57. Dowie, J. (1996b) The research - practice gap and the role of decision analysis in closing it. Health Care Analysis, 4, 5-18.
58. Dujovne, C.A. (2002) Side effects of statins: hepatitis versus 'transaminitis' - myositis versus 'CPKitis. American Journal of Cardiology, 89, 1411-13.
59. Edwards A, Elwyn G, Mulley A (2002). Explaining risks: turning numerical data into meaningful pictures. British Medical Journal; 324:827-830
60. Edwards, R. and Hugman, B. (1997) The challenge of effectively communicating risk-benefit information. Drug Safety, 17, 216-27.
61. Edwards, R., Wiholm, B.-E. and Martinez, C. (1996) Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Safety, 15, 1-7.
62. Electronic Medicines Compendium (2004) [Database on the Internet]. Datapharm Communications Ltd. http://emc.medicines.org.uk (accessed 20 March 2009).
63. Elwyn, G., Edwards, A. and Britten, N. (2003) 'Doing prescribing': how doctors can be more effective. British Medical Journal, 327, 864-7.
64. Eriksen, S. and Keller, L.R. (1993) A multiattribute-utility-function approach to weighing the risks and benefits of pharmaceutical agents. Medical Decision Making, 13, 118-25.
65. Ernst, E. and Resch, K.L (1996) Risk-benefit ratio or risk-benefit nonsense? Journal of Clinical Epidemiology, 49, 1203-4.
66. European Commission (1999) A guideline on summary of product characteristics (final, revision 0). Enterprise Directorate General, Unit F2; December 1999. http://ec.europa.eu/enterprise/ (accessed 6 April 2009).
67. European Commission (2004) Commission proposes regulation aimed at promoting medicines for children [press release]. Enterprise Directorate General, Unit F2; 2004. http://ec.europa.eu/enterprise/ (accessed 6 April 2009).
68. European Council Regulation (EEC) No 2309/93. Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European gency for the Evaluation of Medicinal Products, 22 July 1993.
69. European Council Regulation (EC) No 726/2004. Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, 31 March 2004.
70. European Medicines Agency (2004) Guidance document; (co-)rapporteur day 70 critical assessment report. Revision 1. The European Medicines Agency; 2004 September. http://www.emea.europa.eu (accessed 6 April 2009).
71. European Medicines Agency (2007a) European Medicines Agency finalises review of antidepressants in children and adolescents. EMEA/CHMP/128918/2005corr. 25 April 2005, London UK.
72. European Medicines Agency (2007b) Report of the CHMP Working Group on Benefit-risk Assessment Models and Methods. EMEA/CHMP/15404/2007. 19 January 2007, London UK.
73. European Medicines Agency. EPARs for authorised medicinal products for human use. London. http://www.emea.europa.eu/htms/human/epar/eparintro.htm (accessed March 22, 2009).
74. European Parliament and Council of the European Union. Parliament Directive No. 2001/83/EC. The Community code relating to medicinal products for human use. 6 November 2001.
75. Evans, S. (2008) Special section: benefit:risk evaluation in clinical trials. Drug Information Journal, 42, 221.
76. FDA (1998) US Food and Drug Administration. Guidance for Industry: Providing clinical evidence of effectiveness, May 1998, Rockville, MD. www.fda.gov/CDER/GUIDANCE/1397fnl.pdf (accessed 22 March 2009).
77. FDA (2007) FDA proposes new warnings about suicidal thinking, behavior in young adults who take antidepressant medications. May 2007 Rockville, MD. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html (accessed March 23 2009).
78. Federal Food, Drug and Cosmetic Act (1997) Chapter 5, subchapter A drugs and devices, section 505.355, paragraph d (amended by the 1997 FDA Modernization Act). http://www.fda.gov/opacom/laws (accessed 20 March 2009).
79. Felli, J.C., Noel, R.A. and Cavazzoni, P.A. (2008) A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives. Medical Decision Making, 29, 104-15.
80. Fitzgerald, J.D. (1987) Clinical benefits, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 127-34.
81. Food and Drug Administration (1988) CDER. Guideline for the format and content of the clinical and statistical sections of an application, July 1988. http://www.fda.gov/cder (accessed 20 March 2009).
82. Food and Drug Administration (1998) Guidance for industry; providing clinical evidence of effectiveness for human drug and biological products, FDA, May 1998. Available from http://www.fda.gov/cder (accessed 20 March 2009).
83. Food and Drug Administration (1999a) CDER Special Report. Benefit versus risk: how CDER approves new drugs. In: From test tube to patient: improving health through human drugs.
84. Food and Drug Administration, FDA, 1999. Available from http://www.fda.gov/cder
85. Food and Drug Administration (1999b) Managing the risks from medical product use; creating a risk management framework. Report to the FDA Commissioner from the task force on risk management. FDA, 1999 May. http://www.fda.gov/cder (accessed 20 March 2009).
86. Food and Drug Administration (2001) Letter from J. Woodcock, Director of CDER, to consumers and health care providers, January 9 2001. http://www.fda.gov/cder (accessed 20 March 2009).
87. Food and Drug Administration (2002) CDER consumer information. Think it through: a guide to managing the benefits and risks of medicines FDA, 2002. http://www.fda.gov/cder (accessed 20 March 2009).
88. Food and Drug Administration (2003a). Concept paper; premarketing risk assessment [draft], 2003 March 3. http://www.fda.gov/cder (accessed 20 March 2009).
89. Food and Drug Administration (2003b) Concept paper; risk assessment of observational data: good pharmacovigilance practices and pharmacoepidemiologic assessment [draft], March 3 2003. http://www.fda.gov/cder (accessed 20 March 2009).
90. Food and Drug Administration (2004) Center for Drug Evaluation and Research. Manual of policies and procedures; clinical review template. http://www.fda.gov/cder (accessed 20 March 2009).
91. Friedman, M.A., Woodcock, J., Lumpkin, M.M., et al. (1999) The safety of newly approved medicines; do recent market removals mean there is a problem? Journal of the American Medical Association, 281, 1728-34.
92. Galson, S. (2007) Reducing the risks and increasing the benefits of marketed drugs - FDA response to the IOM report. Presentation to the American College of Preventative Medicine, 24 February 2007. www.fda.gov/cder/present/galson/2007/ACPM022407FINAL.pdf (accessed March 23 2009).
93. Garratt, A., Schmidt, L., Mackintosh, A. and Fitzpatrick, R. (2002) Quality of life measurement: bibliographic study of patient assessed health outcome measures. British Medical Journal, 324, 1417-21.
94. Garrison, L. (2007) A structured health outcomes approach to the pre-marketing quantitative risk-benefit modeling of new pharmaceuticals. Presented at the Benefit-risk Assessments for Drugs Workshop. Office of Health Economics, 24 October 2007, London, UK.
95. Garrison, L.P., Towse, A. and Bresnahan, B. (2007) Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Affairs 26(3), 684-95.
96. Gelber, R.D., Cole, B.F., Gelber, S. and Goldhirsch, A. (1996) The Q-TwiST method, in Quality of Life and Pharmacoeconomics in Clinical Trials (ed. B. Spilker), Lippincott-Raven Publishers, Philadelphia, pp. 403-12.
97. Gift, T.L., Haddix, A.C. and Corso, P.S. (2003). Cost-effectiveness analysis, in Prevention Effectiveness; a Guide to Decision Analysis and Economic Evaluation, 2nd edn (eds A.C. Haddix, S.M. Teutsch and Corso P.S.), Oxford University Press, Oxford, pp. 156-77.
98. Gold, M.R., Siegel, J.E., et al. (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York.
99. Greenhalgh, T. (1997) How to read a paper; the basics of evidence based medicine. BMJ Publishing Group, London.
100. Gruchalla, R.S. (2000) Clinical assessment of drug-induced disease. Lancet, 356, 1505-11.
101. Guyatt, G.H., Sackett, D.L., Cook, D.J., for the evidence-based medicine working group (1993) Users' guide to themedical literature; II. How to use an article about therapy or prevention;A. are the results of the study valid? Journal of the American Medical Asssociation, 270, 2598-601.
102. Guyatt, G.H., Sinclair, J., Cook, D.J. and Glasziou, P. (1999) Users' guide to the medical literature: XVI. How to use a treatment recommendation. Journal of the American Medical Association, 281, 1836-43.
103. Hauber, A.B., Johnson, F.R. and Andrews, E.A. (2006) Risk-benefit analysis methods for pharmaceutical decision-making - where are we now? ISPOR Connections, 12(6), 3-5.
104. Heeley, E., Waller, P. and Moseley, J. (2005) Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study. Drug Safety, 28(10), 901-6.
105. Herxheimer, A. (2001) Benefit, risk and harm. Australian Prescriber, 24, 18.
106. Holden, W.L. (2003) Benefit-risk analysis: a brief review and proposed quantitative approaches. Drug Safety, 26, 853-62.
107. Holden, W.L., Juhaeri, J. and Dai, W. (2003a) Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiology and Drug Safety, 12, 611-16.
108. Holden, W.L., Juhaeri, J. and Dai, W. (2003b) Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiology and Drug Safety, 12, 693-7.
109. Honig, P. (2007) Benefit and risk assessment in drug development and utilization: a role for clinical pharmacology. Clinical Pharmacological Therapy, 82, 109-12.
110. Hughes, D.A., Bayoumi, A.M. and Pirmohamed, M. (2007) Current assessment of risk-benefit by regulators: is it time to introduce decision analysis. Clinical Pharmacology & Therapeutics, 82, 123-7.
111. Hyslop, D.L., Read, H.A., Masica, D.N. and Kotsanos, J.G. (2002) Pharmaceutical risk management: a call to arms for pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 11, 417-20. Institute of Medicine. Drug safety report. September 2006, Washington DC.
112. International Conference on Harmonisation. E9Statistical principles for clinical trials. September 1998. http://www.fda.gov/cder/guidance/ICH_E9fnl.PDF
113. International Conference on Harmonisation (1995a) ICH topic E1A: Population exposure: the extent of population exposure to assess clinical safety, The European Medicines Evaluation Agency. http://www.emea.europa.eu (accessed 7 April 2009).
114. International Conference on Harmonisation (1995b) ICH topic E2A: Clinical safety data management: definitions and standards for expedited reporting, The European Medicines Evaluation Agency. http://www.emea.europa.eu (accessed 7 April 2009).
115. International Conference on Harmonisation (1996a) ICH topic E3: Structure and content of clinical study reports. The European Medicines Evaluation Agency. http://www.ich.org/cache/compo/475-272-1.html#E3 (accessed 6 April 2009).
116. International Conference on Harmonisation (1996b) ICH topic E6: Guideline for good clinical practice. The European Medicines Evaluation Agency. http://www.ich.org/cache/compo/475-272-1.html#E6 (accessed 6 April 2009)
117. International Conference on Harmonisation (1997) ICH topic E8: General considerations for clinical trials. The European Medicines Evaluation Agency. http://www.emea.europa.eu (accessed 7 April 2009).
118. International Conference on Harmonisation (1998) ICH topic E9: Statistical principles for clinical trials. The European Medicines Evaluation Agency. http://www.emea.europa.eu (accessed 7 April 2009).
119. International Conference on Harmonisation (2000) ICH topic M4: Common technical document for the registration of pharmaceuticals for human use. The European Medicines Evaluation Agency. http://www.emea.europa.eu (accessed 7 April 2009).
120. International Conference on Harmonisation (2004) [Homepage on the Internet]. Available from http://www.ich.org (accessed 20 March 2009).
121. Japan Pharmaceutical Manufacturers Association (2003) Pharmaceutical administration and regulations in Japan, JPMA. http://www.jpma.or.jp/index.html (accessed 20 March 2009).
122. Johnson, F.R. and Hauber, A.B. (2007) Quantitative risk-benefit analysis for regulatory decision making: Alternatives and challenges. Presented at the Benefit-risk Assessments for Drugs Workshop. Office of Health Economics, 24 October 2007, London, UK.
123. Johnson, F.R., Fillit, H., et al. (2007a) Alzheimer's disease progression healthy-year equivalents: Stated risk-benefit trade-off preferences. International Conference on Prevention of Dementia, Washington, DC. June 2007. http://www.rtihs.org/request/index.cfm?fuseaction1/4display&PID1/49517 (accessed 23 March 2009).
124. Johnson, F.R., Ozdemir, S. et al. (2007b) Women's willingness to accept perceived risks for vasomotor symptom relief. Journal of Womens Health, 16(7), 1028-40.
125. Johnson, N., Lilford, R.J., Mayers, D., et al. (1994) Do healthy asymptomatic postmenopausal women with a uterus want routine cyclical hormone replacement? A utility analysis. Journal of Obstetrics and Gynaecology, 14, 35-9.
126. Johnson, F.R., Ozdemir, S., Mansfield, C., et al. (2007) Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology, 133(3), 769-79.
127. Jones, R. (2002) Efficacy and safety of COX 2 inhibitors. British Medical Journal, 325, 607-8.
128. Kaufman, D.W. and Shapiro, S. (2000) Epidemiological assessment of drug induced disease. Lancet, 356, 1339-43.
129. Keeney, R.L. (1992) Value-Focused Thinking: a Path to Creative Decision-Making, Harvard University Press, Cambridge, MA, USA.
130. Keeney, R.L. and Raiffa, H. (1976) Decisions with multiple objectives, John Wiley & Sons, New York.
131. Kessler, D.A., Pape, S.M. and Sundwall, D.N. (1987) The Federal regulation of medical devices. New England Journal of Medicine, 317, 357-66.
132. Kirkwood, C.W. (1996) Strategic Decision Making: Multiobjective Decision Analysis with Spreadsheets, Wadsworth Publishing Co, Belmont, CA, USA, 1996.
133. Konstam, M. (2003) Matters of the heart: assessing the cardiovascular safety of new drugs. American Heart Journal, 146, 561-2.
134. Kruse, W., Eggert-Kruse, W., Rampmaier, J., et al. (1991) Dosage frequency and drug compliance behaviour; a comparative study on compliance with a medication to be taken twice or four times daily. European Journal of Clinical Pharmacology, 41, 589-92.
135. Lasagna, L. (1998) Balancing risks versus benefits in drug therapy decisions. Clinical Therapeutics, 20, C72-C79.
136. Lasser, K.E., Allen, P.D., Woolhandler, S.J., et al. (2002) Timing of new black box warnings and withdrawals for prescription medications. Journal of the American Medical Association, 287, 2215-20.
137. Laupacis, A., Sackett, D.L. and Roberts, R.S. (1988) An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine, 318(26), 1728-33.
138. Lebow, M.A. (1999) The pill and the press: reporting risk. Obstetrics & Gynecology, 93, 453-6.
139. Lee, T.R. (1987) The risks in society, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 5-12.
140. Lehner, J.P., Meyer, F., Juillet, Y., les participants a` la table ronde no. 1 de Giens XVI (2001) Communication et transparence de l'évaluation du risque et bénéfice en santé publique: exemple du médicament. Thérapie, 56, 335-9.
141. Lewis, J.H. (1993) Risk/benefit assessment of new drugs: perspectives of a former FDA Advisory Committee member. Drug Information Journal, 27, 1037-49.
142. Lilford, R.J. and Braunholtz, D. (1996) For debate: the statistical basis for public policy: a paradigm shift is overdue. British Medical Journal, 313, 603-7.
143. Lilford, R.J. and Jackson, J. (1995) Equipoise and the ethics of randomisation. Journal of the Royal Society of Medicine, 88, 552-9.
144. Lilford, R.J., Pauker, S.G., Braunholtz, D.A. and Chard, J. (1998) Decision analysis and the implementation of research findings. British Medical Journal, 317, 405-9.
145. Llewellyn-Thomas, H.A., Williams, J.I., Levy, L. and Naylor, C.D. (1996) Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Medical Decision Making, 16, 262-72.
146. Localio, A.R., Margolis, D.J. and Berlin, J.A. (2007) Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. Journal of Clinical Epidemiology, 60, 874-82.
147. Loke, Y.K., Bell, A. and Derry, S. (2003) Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient. British Journal of Clinical Pharmacology, 55, 282-7.
148. Lumpkin, M.M. (2000) International pharmacovigilance: developing cooperation to meet the challenges of the 21st century. Pharmacology & Toxicology, 86 (Suppl I), 20-2.
149. Lynd, L.D. (2007a) An example of incremental net benefit analysis using Lotronex, in Drug Information Association 43rd Annual Meeting, 2007, Atlanta, USA.
150. Lynd, L.D. (2007b) Using incremental net benefit for quantitative benefit-risk analysis - Case studies of Vioxx and Lotronex. Presented at the Benefit-risk Assessments for Drugs Workshop. Office of Health Economics, 24 October 2007, London, UK.
151. Lynd, L.D. and O'Brien, B.J. (2004) Advances in risk benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis. Journal of Clinical Epidemiology, 57, 795-803.
152. MacGregor, A.D. and Perry, W.L. (1962) Detection of drug toxicity. Lancet, 1, 1233.
153. McGregor, M. and Caro, J.J. (2006) QALYs: are they helpful to decision makers? Pharmacoeconomics, 24(10), 947-52.
154. Mancini, G.B.J. and Schulzer, M. (1999) Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation, 99, 377-83.
155. Martin, A.J., Lumley, T.S. and Simes, R.J. (1996) Incorporating trade-offs in quality of life assessment, in Quality of Life and Pharmacoeconomics in Clinical Trials (ed. B. Spilker), Lippincott-Raven Publishers, Philadelphia, pp. 403-12.
156. Martindale (2002) The Complete Drug Reference, 33th edn (ed. S.C. Sweetman), Pharmaceutical Press, London.
157. Marwick, C. (1999) Drug safety takes cooperation. Journal of the American Medical Association, 282, 315-16.
158. Matheson, D. and Matheson, J. (1998) The Smart Organization: Creating Value Through Strategic R&D. Harvard Business School Press, Boston.
159. Medicines Evaluation Board (1999) Public assessment report Maxalt. Available from http://www.cbg-meb.nl/CBG/en/human-medicines/actueel/1999-03-01-Public{thorn}Assessment{thorn}Report{thorn}of{thorn} the{thorn}Medicines{thorn}Evaluation{thorn}Board{thorn}Rizatriptan{thorn}Maxalt/default.htm (accessed 6 April 2009).
160. Meiners, A.P. (2002) Transparency and communication of the benefit-risk assessment, patients' expectations [presentation], Drug Information Association Annual Euromeeting 2002, Basel, Switzerland, March 6, 2002. http://www.diahome.org (accessed 20 March 2009).
161. Messonnier, M. and Meltzer, M. (2003) Cost-benefit analysis, in Prevention Effectiveness: a Guide to Decision Analysis and Economic Evaluation, 2nd edn (eds A.C. Haddix, S.M. Teutsch and P.S. Corso), Oxford University Press, Oxford, pp. 127-55.
162. Meyboom, R.H.B. and Egberts, A.C.G. (1999) Comparing therapeutic benefit and risk. Thérapie, 54, 29-34.
163. Miller, L.L. (1992) Pitfalls in the drug approval process: dose-effect, experimental design, and risk-benefit issues. Drug Information Journal, 26, 251-60.
164. Miller, L.L. (1993) Risk/benefit assessment: the 'greased pig' of drug development. Drug Information Journal, 27, 1011-20.
165. Moher, D., Schulz, K.F., Altman, D.G., for the CONSORT group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet, 357, 1191-4.
166. Moynihan, R., Bero, L., Ross-Degnan, D., et al. (2000) Coverage by the news media of the benefits and risks of medications. New England Journal of Medicine, 342, 1645-50.
167. Mussen, F. (2001) Balancing risks and benefits - science or opinions [unpublished communication]. Management Forum seminar (in association with the Medicines Control Agency) 'Risk Benefit Assessment', November 8, 2001, London.
168. Mussen,F. (2002)Balancingrisks and benefits - science or opinions [unpublished communication]. Management Forum seminar 'Benefit Risk Assessment', November 29, 2002, London.
169. Mussen, F. (2005) The evaluation of methods for benefit risk assessment of medicines and the development of a new model using multi criteria decision analysis. Doctoral Thesis, University of Wales.
170. Mussen, F., Salek, S. and Walker, S. (2007) A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiology and Drug Safety, 16, S2-S15.
171. Naimark, D., Krahn, M.D., Naglie, G., et al. (1997) Primer on medical decision analysis: part 5 -working with Markov processes. Medical Decision Making, 17, 152-59.
172. Naito, C. (1994) Evaluation methods for clinical trials of drugs in Japan which may affect ethnic differences, in The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines (ed. S. Walker), Kluwer Academic, Boston, pp. 49-62.
173. National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal. April 2004, NICE, London.
174. Naylor, C.D. and Llewellyn-Thomas, H.A. (1994) Can there be a more patient-centred approach to determining clinically important effect sizes for randomised treatment trials? Journal of Clinical Epidemiology, 47, 787-95.
175. Official Journal of the European Communities (2004) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, Official Journal L 136, 30/04/2004, 34-84.
176. O'Neill, R. (2008) A perspective on characterizing benefits and risks derived from clinical trials: can we do more? Drug Information Journal, 42, 235-44.
177. PatientView (2002) EU patients do not trust doctors and pharmacists to give satisfactory information on prescribing drugs [press release], 2002 June. http://www.patient-view.com (accessed 20 March 2009).
178. Patten, S.B. and Lee, R.C. (2002) Modeling methods for facilitating decisions in pharmaceutical policy and population therapeutics. Pharmacoepidemiology and Drug Safety, 11, 165-8.
179. Pearce, L.B., Pitman, A., Greenburg, A.G., et al. (2008) Application of a unique scoring system for numerical determination of a benefit risk ratio in clinical trials. Clinical Pharmacology & Therapeutics, 83, S87-S88.
180. Penfornis, A. (2003) Observance médicamenteuse dans le diabe`te de type 2: influence des modalités du traitement médicamenteux et conséquences sur son éfficacité. Diabetes & Metabolism, 29 (suppl), S31-S37.
181. Perfetto, E.M., Ellison, R., Ackermann, S., et al. (2003) Evidence-based risk management: how can we succeed? Deliberations from a risk management advisory council. Drug Information Journal, 37, 127-34.
182. Phillips, L. (2007) Multi-criteria decision analysis. Presented at the Benefit-risk Assessments for Drugs Workshop, Office of Health Economics, 24 October 2007, London, UK.
183. Phillips, L.D. and Costa, C.A.B. (2007) Transparent prioritisation, budgeting and resource allocation with multi-criteria decision analysis and decision conferencing. Annals of Operations Research, 154(1), 51-68.
184. Physicians' Desk Reference (2008) PDR Electronic Library, The Thomson Corporation.
185. Piantadosi, S. (1995) David Byar as a teacher. Controlled Clinical Trials, 16, 202-11.
186. Pignatti, F., Aronsson, B., Vamvakas, S., et al. (2002) Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology. Critical Reviews in Oncology/ Hematology, 42, 123-35.
187. Pitt, B., Poole-Wilson, P., Segal, R., et al (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet, 355, 1582-7.
188. Pocock, S.J. (1996) Clinical Trials: a Practical Approach, John Wiley & Sons, Chichester.
189. Pritchett, Y.L. and Tamura, R. (2007) Global benefit-risk assessment in designing clinical trials and some statistical considerations of the method. Pharmaceutical Statistics, 7, 170-8.
190. Puliyel, J.M. (2002) The dummies' guide to risk-benefit analysis of vaccines. Pediatrics, 110, 193.
191. Rawlins, M.D. (1987) Risk-benefit decisions in licensing changes, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 137-41.
192. Rawlins, M.D. (1995) Pharmacovigilance: paradise lost, regained or postponed? Journal of the Royal College of Physicians of London, 29, 41-9.
193. Risk:benefit analysis of drugs in practice; the doctor the patient and the licensing authority (1995). Drug and Therapeutics Bulletin, 33, 33-5.
194. Rothenberg, M.L., Carbone, D.P. and Johnson, D.H. (2003) Improving the evaluation of new cancer treatments: challenges and opportunities. Nature Reviews - Cancer, 3, 303-9.
195. Sawaya, G.F., Guirguis-Blake, J., LeFevre, et al., for the US Preventive Services Task Force (2007) Update on the methods of the US Preventive Services Task Force: estimating certainty and magnitude of net benefit. Annals of Internal Medicine, 147, 871-5.
196. Slovic, P. (1987) Perception of risk. Science, 236, 280-5.
197. Schiller, L.R. and Johnson, D.A. (2008) Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. American Journal of Gastroenterology, 103, 815-19.
198. Schosser, R. (2002) Risk/benefit evaluation of drugs: the role of the pharmaceutical industry in Germany. European Surgical Research, 34, 203-7.
199. SCRIP (2000) Rezulin was 'outmoded', says FDA, SCRIP, 2542, 20.
200. Shaffer, M.L. and Watterberg, K.L. (2006) Joint distribution approaches to simultaneously quantifying benefit and risk. BMC Medical Research Methodology, 6, 48.
201. Shakespeare, T.P., Gebski, V.J., Veness, M.J. and Simes, J. (2001) Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet, 357, 1349-53.
202. Simon, L.S. (2002) Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Annals of the Rheumatic Diseases, 61 (suppl II), ii88-ii89.
203. Skolbekken, J.-A. (1998) Communicating the risk reduction achieved by cholesterol reducing drugs. British Medical Journal, 316, 1956-8.
204. Slovic, P. (1987) Perception of risk. Science, 236, 280-5.
205. Smeeth, L., Haines,A. and Ebrahim, S. (1999)Numbers needed to treat derived frommeta-analyses -sometimes informative, usually misleading. British Medical Journal, 318, 1548-51.
206. Smith, G.D. and Egger, M. (1994) Who benefits from medical interventions? British Medical Journal, 308, 72-4.
207. Spilker, B. (1994) Incorporating benefit-to-risk determinations in medicine development. Drug News & Perspectives, 7, 53-9.
208. Swales, J.D. (1997) Science in a health service. Lancet, 349, 1319-21.
209. Tan, L.B. and Murphy, R. (1999) Shifts in mortality curves: saving or extending lives? Lancet, 354, 1378-81.
210. Taylor, R.S., Drummond, M.F., Salkeld, G. and Sullivan, S.D. (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. British Medical Journal, 329, 972-5.
211. Temple, R.J. and Himmel, M.H. (1999) Safety of newly approved drugs: implications for prescribing. Journal of the American Medical Association, 287, 2273-5.
212. Temple, R. (2007) Quantitative decision analysis: a work in progress. Clinical Pharmacology & Therapeutics, 82, 127-30.
213. The School of Community, Health Sciences and Social Care (2000) Validity. University of Salford. http://www.chssc.salford.ac.uk/healthSci/resmeth2000/remeth/validity.htm (accessed 22 March 2009).
214. The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine, 325, 193-302.
215. The Uppsala Monitoring Centre (2002a) Benefit, harm, effectiveness and risk in medicine, in Viewpoint part I. WHO Collaborating Centre for International Drug Monitoring, Uppsala.
216. The Uppsala Monitoring Centre (2002b) The risks of being alive, in Viewpoint part I. WHO Collaborating Centre for International Drug Monitoring, Uppsala.
217. Thompson, I.M., Klein, E.A., Lippman, S.M., et al. (2003) Prevention of prostate cancer with finasteride: A US/European perspective. European Urology, 44, 650-5.
218. Troche, C.J., Paltiel, A.D. and Makuch, R.W. (2000) Evaluation of therapeutic strategies: a new method for balancing benefit and risk. Value in Health, 3, 12-22.
219. Urquhart, J. (2001) Mis- and non-use of prescription drugs: confusion, lost revenues and future commercial opportunities. Pharmaceutical Visions, summer, 9-17.
220. Valuck, R.J., Libby, A.M., et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with selective serotonin reuptake inhibitors. American Journal of Psychiatry, 164(8), 1198-205.
221. VanTrigt, A.M., De Jong-Van DenBerg, L.T.W., Voogt, L.M., et al. (1995) Setting the agenda: does the medical literature set the agenda for articles about medicines in the newspapers? Social Science & Medicine, 41, 893-9.
222. Veatch, R.M. (1993) Benefit/risk assessment: what patients can know that scientists cannot. Drug Information Journal, 27, 1021-9.
223. Vioxx: an unequal partnership between safety and efficacy (2004) Lancet, 364, 1287-8.
224. Walker, S.R. (1987) Introductory remarks, in Medicines and Risk/Benefit Decisions (eds S.R. Walker and A.W. Asscher), MTP Press Limited, Lancaster, pp. 1-2.
225. Waller, P. (2001) Pharmacoepidemiology - a tool for public health. Pharmacoepidemiology and Drug Safety, 10, 165-72.
226. Walker, S. and Cone, M. (2004) Benefit-risk Assessment: Summary Report on the Workshop on the Development of a Model for Benefit-risk Assessment of Medicines Based on Multi-Criteria Decision Analysis. Centre for Medicines Research International, 2004, Surrey, UK.
227. Walker, S., Phillips, L.D., et al. Benefit-risk Assessment Model for Medicines: Developing a Structured Approach to Decision Making. Epsom: Centre for Medicines Research International, 2006, Surrey, UK.
228. Waller, P.C. and Evans, S.J.W. (2003) A model for the future conduct of pharmacovigilance. Pharmacoepidemiology and Drug Safety, 12, 17-29.
229. Wardell, W.M. (1973) Therapeutic implications of the drug lag. Clinical Pharmacology and Therapeutics, 15, 73-96.
230. Webster's Ninth New Collegiate Dictionary (1991) 9th edn. Merriam-Webster, Springfield.
231. Whitebrook, J. and Markey, J. (2008) Industry and regulatory survey of benefit-risk management best practices. Proceedings of the Drug Information Association Annual Meeting, Boston, USA, 2008, p. 89.
232. WHO Collaborating Centre for International Drug Monitoring (2004) Definitions [Internet page]. The Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring [updated 2004 October 11]. http://www.who-umc.org (accessed 7 April 2009).
233. Willan, A.R., O'Brien, B.J. and Cook, D.J. (1997) Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Controlled Clinical Trials, 18, 121-30.
234. Wood, A.J.J. (1999) The safety of new medicines: the importance of asking the right questions. Journal of the American Medical Association, 281, 1753-4.
235. World Health Organization (2003) Adherence to Long-term Therapies: Evidence for Action, World Health Organization, Geneva.